Thomson Reuters analysts have disclosed 10 deals – five biopharma licensing and five M&A deals concluded in 2014 – as candidates for the Breakthrough Alliance Awards, with voting now open and the winner to be announced at this year's Allicense meeting in San Francisco. Read More
HONG KONG – Known already as the first China-manufactured biologic used in U.S. trials, HIV candidate ibalizumab (TMB-355) won FDA breakthrough therapy designation, which could substantially accelerate the product's launch. Read More
SHANGHAI – The evolving story of CASI Pharmaceuticals Inc. is about a Nasadaq-listed firm hoping for a fresh start as a China-focused oncology company without letting go of its American roots. Read More
HONG KONG – A study led by Singaporean researchers has identified a potent new antibody against the dengue virus, a minimal amount of which is required to neutralize it, which is an important finding that may lead to the development of effective new treatments or vaccines. Read More
SHANGHAI – Making a strong move to enter China's cardiovascular (CDV) market, Shanghai-based Eddingpharm Co. Ltd. inked a deal with Amarin Corp. plc, of Dublin, to bring Vascepa to Greater China. Amarin will receive a nonrefundable $15 million up-front payment, while the total deal is valued at $169 million in milestones and tiered sales royalties. Read More
TAIPEI, Taiwan – Companies across Southeast Asia are taking multiple steps to develop or attract more innovation and power their biotechnology industries. Read More
